PA-SYNERGIS-SOFTWARE
28.10.2020 13:23:34 CET | Business Wire | Press release
Synergis Software , a global leader in engineering information management and product data management (PDM), today announced that its flagship product, Adept, has earned 21 top placements in G2 Crowd ’s Fall 2020 Grid Reports.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005422/en/
The reports, which are based on real customer reviews, highlight Adept’s leadership in ease of use, ease of setup, fastest implementation, best support and best relationship as some of the key differentiators compared to other products on the market.
Adept earned Leader status in Product Data Management (PDM) and Enterprise Content Management (ECM), and High Performer status in Construction Drawing Management.
“We're committed to helping clients become more efficient, secure and collaborative, and reports like this help us understand what we're doing well and how we can improve,” said Scott Lamond, vice president of marketing at Synergis Software. “We’re energized and honored that the voice of the customer has us ranked at the top of our field.”
Adept also achieved an exceptional 77 on the G2 Net Promoter Scorecard (NPS).
According to G2, “The purpose of NPS is to gauge customer loyalty to a brand, and how likely they are to recommend your product to a peer. An NPS at-or-above 70 is considered “world class.” Essentially, this means nearly every customer would advocate for that product."
Here’s what some Adept customers had to say:
- “Data is the cornerstone of any business today and not securing it is a huge risk. If you want to do it right and do it well, the Adept platform is the gold-standard.”
- “No other software company anywhere works as closely with their customers. For a system that your business cannot operate without, this is invaluable.”
- “An immediate 30% gain in user efficiency”
Adept earned top honors in the following rankings:
Product Data Management - Best Usability, Easiest Setup, Fastest Implementation, Most Implementable, Ease of Administration, Ease of Doing Business, Quality of Support, Best Relationship, Most Likely to Recommend, Highest Net Promoter Score
Construction Drawing Management - Easiest to Use, Best Meets Requirements, Easiest Setup, Best Support, Highest User Adoption, Easiest to do Business With, Product Going in the Right Direction, Most likely to Recommend, Highest Net Promoter Score
Enterprise Content Management - Ease of Doing Business With, Best Search Capabilities
To see how Adept stacks up, download the full comparison report .
You can read more customer feedback on G2’s Adept review page .
Learn more about G2’s scoring methodology here .
About Synergis Software
Synergis Software is the leader in engineering document management and product data management, helping businesses become more efficient, secure and collaborative. The flagship product, Adept, gets everyone on the same page, simplifying the way organizations find, manage, share and integrate enterprise content. Adept streamlines engineering change management, protects intellectual property, and provides data insights to improve decision making. Adept is integrated with AutoCAD®, Autodesk Inventor®, SolidWorks® and MicroStation®, and has been battle tested by engineers for over 30 years in customers like Dow Chemical, Con Edison, General Mills, Bayer, and Nucor Steel.
G2 Crowd
G2 Crowd , the world's leading business solution review platform, leverages more than 790,000 user reviews to drive better purchasing decisions. G2 aims to bring authenticity and transparency to the business marketplace by leveraging peer reviews, satisfaction scores, and synthesized social data.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005422/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
